Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Recombinant human interferon alpha nose drops and its production technology

A technology of recombinant human interferon and nasal drops, which is applied in antiviral agents, peptide/protein components, medical preparations containing active ingredients, etc., can solve the problems of inconvenient use, pain and adverse reactions, and avoid pain , Avoid adverse reactions, easy to use

Inactive Publication Date: 2003-04-16
CHANGCHUN CHANGSHENG GENE PHARM CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main dosage form is injection, but in clinical use, pain and adverse reactions (fever, etc.) caused by injection often occur, especially for children and the elderly, and it is very inconvenient to use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Take 80ml of sterilized water for injection at 60℃~70℃ into a 100ml measuring cylinder, add 0.85g of sodium chloride, 0.03g of methylparaben, 0.01g of propylparaben, 4g of dextran, and 1g of mannitol, and stir to make Fully dissolve, add interferon after cooling to make 1 million IU / ml, dilute to 100ml with sterile water for injection, mix well, filter with 0.22μm filter membrane for sterilization, and pack aseptically.

Embodiment 2

[0015] Take 80ml of sterilized water for injection at 60℃~70℃ into a 100ml measuring cylinder, add 0.85g of sodium chloride, 0.005g of thimerosal, 3g of dextran, 2g of mannitol, and 0.2g of methylcellulose and stir to fully dissolve. After cooling, add Interferon is made into 500,000 IU / ml, diluted with sterile water for injection to 100ml, mixed evenly, filtered with a 0.22μm filter membrane, and aseptically dispensed.

Embodiment 3

[0017] Take 80ml of sterilized water for injection at 60℃~70℃ into a 100ml measuring cylinder, add 0.85g of sodium chloride, 0.03g of methylparaben, 0.01g of propylparaben, 4g of dextran, 3g of mannitol, hyaluronic acid Stir 0.1g of sodium to fully dissolve, add interferon after cooling to make 500,000 IU / ml, dilute to 100ml with sterile water for injection, mix well, filter it with a 0.22μm filter membrane, and pack aseptically.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A recombinant human interferon alpha nose-drops for preventing and treating influenza, upper respiratory tract infection and fever is prepared from recombinant human interferon, protecting agent, thickening agent and antiseptic.

Description

Technical field: [0001] The invention relates to a new dosage form of recombinant human interferon, in particular to recombinant human interferon alpha nasal drops and a production process, belonging to the technical field of biopharmaceuticals. Background technique: [0002] As a mature product of genetic engineering, interferon is currently recognized as the first choice drug for the treatment of viral diseases at home and abroad. The main dosage form is injection, but when used clinically, pain and adverse reactions (fever, etc.) caused by injection often occur, especially for children and the elderly, which is very inconvenient to use. Invention content: [0003] The invention discloses a recombinant human interferon α nasal drop and its production process, and provides a nasal administration as a new interferon dosage form, which is mainly used for treating influenza, upper respiratory tract infection, fever, etc. caused by viruses disease. [0004] The technical so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/21A61P31/12
Inventor 李英章春宇郭秀侠张淑子黄宇
Owner CHANGCHUN CHANGSHENG GENE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com